Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
23.75
-0.45 (-1.86%)
At close: Nov 17, 2026
SHA:688443 Revenue
Chongqing Genrix Biopharmaceutical had revenue of 624.70M CNY in the quarter ending September 30, 2026, with 285.23% growth. This brings the company's total for the last twelve months to 800.98M, up 255.73% year-over-year. In the year 2025, Chongqing Genrix Biopharmaceutical had annual revenue of 230.73M with 666.66% growth. That makes Chongqing Genrix Biopharmaceutical the 21,360th largest company in the world by revenue and 3,917th in China.
Revenue (ttm)
800.98M
Revenue Growth
+255.73%
P/S Ratio
11.08
Revenue / Employee
706.95K
Employees
1,133
Market Cap
8.71B
Revenue by Geography
- Overseas 132.51M 57.4%
- China 98.19M 42.6%
Fiscal year ended Dec 31, 2025 See the full SHA:688443 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 230.73M | 200.63M | 666.66% |
| Dec 31, 2024 | 30.09M | 28.88M | 2,384.11% |
| Dec 31, 2023 | 1.21M | 736.26K | 154.92% |
| Dec 31, 2022 | 475.24K | -38.72M | -98.79% |
| Dec 31, 2021 | 39.19M | 38.10M | 3,502.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 10.74B |
| Pacific Shuanglin Bio-pharmacy | 2.42B |
| Tibet Cheezheng Tibetan Medicine | 2.23B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.16B |
| Shanghai Medicilon | 1.54B |
| Liaoning Chengda Biotechnology | 1.34B |
| Shanghai OPM Biosciences | 822.13M |
| Mabwell (Shanghai) Bioscience | 717.80M |